Several anticancer drugs display characteristics that make them suitable candidates for therapeutic drug monitoring (TDM), including substantial pharmacokinetic variability and a narrow therapeutic index. However, concentration-effect relationships (pharmacodynamics) of most antineoplastic agents have not been well defined, thus limiting the widespread clinical application of TOM for cancer chemotherapy. Strategic For antineoplastics in which the "steep" portion of the concentration-effect curve lies within the range of cm-
were directly related to the doses of drug administered for several drug-sensitive cancers (11). It was also noted that the dose intensity actually delivered to patients was frequently less than that intended in protocol design; this happened for numerous reasons, particularly therapeutic delays required for recoveiy from excessive toxicity (12-14) .
Over the next few years, the concept of dose intensity was expanded to include the element of time over which a cumulative dose was administered, an acknowledgment that delays in drug therapy might allow tumor regrowth to compro- is that the administration of a fixed dose of drug to different patients will produce systemic drug exposures that also vary according to the differences in drug clearance (Figure 1) .
In The relatively narrow therapeutic window for anticancer drugs is depicted in The spectrum of drug toxicity can sometimes be modulated by altering the administration schedule, even at a constant total or cumulative dose. 
. Hypothetical relationsbetweendrugconcentration or exposureand oncolytic response (-) or toxiceffects(---) in differentpatients
Therapeuticwindows (shaded areas) correspondto a probability for responseof at least 50%,whIle the likelihoodof toxicityIsmaintainedbelow 20%. Drug I (left panel) does not producetoxicity at concentrationsclose tothoserequiredfor efficacy.If dosed adequately,two patients bowing tumors of differentdrugsensitivities (A> B) can both attain "ma,drnal" likelihood of an oncolytic response,while still avoiding concentrationsassociated with >20% risk of toxicity (a for patient A, b for patient B). Patient B, having a less sensitive tumor, will require higher concentrations than patient A to produce an equivalent effect; thus, B has a narrower therapeuticwindow, due tothehigherconcentrationneeded to produce50% efficacy. Drug ii (rightpanel) has a propensity to producetoxicities at concentrations similarto those required for therapeuticeffects. Responsecurves A and B represent patientswith differing tumor sensitivities to the drug; dashed curves depict patientsdiffering in predispositionfor experiencingtoxic effects (e.g.,because of prior pretreatmentsor poor performancestatus). Patientswith a sensitive tumor (A) and highthreshold for withstandingtoxicity ( willhavea wide therapeuticwindow (Aa). In contrast,patientswitha refractoiy tumor (B) and poor tolerance totoxicity ( willrequirecontrol of serum concentrationswithin a tighter range (Sb)to maximizeefficacy,whIleavoidingundueriskfortoxicity. Unfortunately,most anticancer drugs resemble DrugII more closely than Drug I concept of "maximizing" therapeutic intensity, i.e., dosof subsequent therapy, optimization of delivered theraing to toxicity. Fig.3 . Assessing the interactingfactors of intrinsic tumor sensitivity to a given drug and systemicexposureto the drug, in relation to overall clinical response Eventhough in vivo systemicexposureandtumorsensltMtymaybe independent prognosticfeatures, the interactionof the two ultimately determines patient response.Patient a, with relatively highsystemic exposureandgoodtumor sensitivity(LC, = concentrationrequired to producelethality in50% of cells), should have a better prognosis than patientb, who has lower systemic exposure to chemotherapy (e.g., faster drug clearance) and has a more resistant tumor. Unfortunately,it has proven difficult to develop In vitro methods for determiningtumor sensitivity to anticancer drugs thatare analogousto culture and sensitivity testing ofbacteria to antibiotics. However,once developed, such methods may provide an objective method for selecting anticancer drugs and identifyingthose patients who would benefit from TOM to maximize systemicexposure to anticancer drugs this usually will obviate the need for TDM of the drug in question (3, 5, 34 and inversely with acute lymphoblastic leukemia (ALL) relapse (51).
1DM In Antlneoplastlc TrIals: PromIsIng PrelimInary Results
In the preceding sections, we developed the rationale for using TDM in antineoplastic therapy by emphasizing the correlation of drug effects to systemic exposure rather than to absolute dose intensity (2-4) 
